Evogene (NASDAQ:EVGN) Stock Price Passes Below 200 Day Moving Average of $0.74

Evogene Ltd. (NASDAQ:EVGN) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.74 and traded as low as $0.64. Evogene shares last traded at $0.66, with a volume of 37,773 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Evogene in a report on Wednesday. They set a “sell” rating for the company.

Evogene Stock Up 1.5 %

The stock has a market cap of $27.19 million, a P/E ratio of -1.24 and a beta of 1.49. The stock has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $0.74.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. The business had revenue of $0.58 million for the quarter, compared to analyst estimates of $1.73 million. Evogene had a negative net margin of 423.39% and a negative return on equity of 76.93%. During the same quarter last year, the firm earned ($0.07) EPS.

Hedge Funds Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. Silverarc Capital Management LLC grew its stake in Evogene Ltd. (NASDAQ:EVGN) by 3,000.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,100,000 shares of the biotechnology company’s stock after buying an additional 3,000,000 shares during the quarter. Silverarc Capital Management LLC owned 7.52% of Evogene worth $1,818,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.